SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

USFDA completes Pre-License inspection at Biocon’s biosimilars site

30 Apr 2026 Evaluate

U.S. Food and Drug Administration (USFDA) has completed a Pre-License Inspection (PLI) at Biocon’s biosimilars site at Biocon Park in Bengaluru, India. The inspection was conducted between April 20, 2026, and April 29, 2026, and covered 3 Biologics Manufacturing units, 5 Quality testing laboratories and 2 Warehouses. 

At the conclusion of the inspection, the USFDA issued a Form 483 with five observations. These observations are procedural in nature and do not pertain to data integrity or quality oversight. There were no repeat observations noted. The Company will submit a comprehensive Corrective and Preventive Action (CAPA) plan within the stipulated timeline and is confident all observations will be addressed fully and expeditiously.

Biocon remains committed to upholding the highest standards of Quality and Compliance and working collaboratively with global regulatory agencies to ensure the safety, efficacy, and reliability of its products.

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.

Biocon Share Price

368.90 8.50 (2.36%)
05-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1820.75
Dr. Reddys Lab 1270.95
Cipla 1333.55
Zydus Lifesciences 911.85
Lupin 2343.40
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×